Aligos Therapeutics Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Great. Welcome back everyone to our next session. I'm Roanna Ruiz, senior biotech analyst here at SVB Securities. And it's my pleasure to introduce the Chairman and CEO of Aligos Therapeutics, Lawrence Blatt. So thanks for joining us. And I will pass it to Lawrence to kick off a presentation on the company.
Thank you, and I want to thank you and the Silicon Valley Bank team for inviting us to this presentation.
So we will be making forward-looking statements today about our portfolio. The Aligos' portfolio consists of several products in early clinical development. Our lead asset in NASH is ALG-009, and this was a in-house discovered purpose-built beta thyroid agonist. We began working on this program about five years ago. And we're just completing our Phase 1 studies and moving into Phase 2 studies.
And I think as most of the audience knows, there's been a recent development for beta thyroid agonism and that is the lead compound for Madrigal
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
